MedTrace Logo

Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis

NCT00622908 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2015-03-24

Study results available
· View outcomes & findings →

Summary

To evaluate the clinical and microbial efficacy of ISV-403 administered three times a day (TID) for 5 days compared to vehicle three times a day for 5 days in the treatment of bacterial conjunctivitis

Conditions

  • Bacterial Conjunctivitis

Interventions

DRUG

ISV-403

0.6% TID, 5 days

DRUG

Vehicle

Vehicle of ISV-403 TID, 5 days

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Timothy Comstock, OD · Bausch & Lomb Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2005-06-30
Completion
2005-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00622908 on ClinicalTrials.gov